The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in nocamels.com
Israeli medical diagnostic company MeMed (opens in a new tab) has announced the successful completion of the first randomized controlled trial in the US of its test to differentiate between bacterial and viral infections.
The test could reduce the amount of use of antibiotics, which do not work on viral infections but whose prescription for them plays a part in the growing problem of antibiotic resistance in bacteria.
The company says the trial of the MeMed BV test successfully demonstrates its clinical utility in promoting appropriate antibiotic use, highlighting its potential to improve patient outcomes and healthcare decision making. It also called the trial a critical step toward making the test the standard for distinguishing bacterial and viral infections.
MeMed Co-founder and CTO Kfir Oved is a Technion alumnus.